Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M507831200 on August 8, 2005

J. Biol. Chem., Vol. 280, Issue 40, 34133-34142, October 7, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/40/34133    most recent
M507831200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ingham, R. J.
Right arrow Articles by Pawson, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ingham, R. J.
Right arrow Articles by Pawson, T.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Epstein-Barr Virus Protein, Latent Membrane Protein 2A, Co-opts Tyrosine Kinases Used by the T Cell Receptor*

Robert J. Ingham{ddagger}1, Judith Raaijmakers{ddagger}, Caesar S. H. Lim{ddagger}§, Geraldine Mbamalu{ddagger}, Gerald Gish{ddagger}, Fu Chen¶, Liudmila Matskova¶2, Ingemar Ernberg¶, Gösta Winberg¶2, and Tony Pawson{ddagger}§3

From the {ddagger}Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada, Karolinska Institutet, Microbiology and Tumor Biology Center, Stockholm SE-171 77, Sweden, and the §Department of Molecular and Medical Genetics, University of Toronto, Toronto, Ontario M5S 1A8, Canada

Received for publication, July 19, 2005


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Epstein-Barr virus (EBV) is the causative agent of infectious mononucleosis and is associated with several human malignancies. The EBV protein latent membrane protein 2A (LMP2A) promotes viral latency in memory B cells by interfering with B cell receptor signaling and provides a survival signal for mature B cells that have lost expression of surface immunoglobulin. The latter function has suggested that LMP2A may enhance the survival of EBV-positive tumors. EBV is associated with several T cell malignancies and, since LMP2A has been detected in several of these disorders, we examined the ability of LMP2A to transmit signals and interfere with T cell receptor signaling in T cells. We show that LMP2A is tyrosine-phosphorylated in Jurkat TAg T cells, which requires expression of the Src family tyrosine kinases, Lck and Fyn. Lck and Fyn are recruited to the tyrosine-phosphorylated Tyr112 site in LMP2A, whereas phosphorylation of an ITAM motif in LMP2A creates a binding site for the ZAP-70/Syk tyrosine kinases. LMP2A also associates through its two PPPPY motifs with AIP4, a NEDD4 family E3 ubiquitin ligase; this interaction results in ubiquitylation of LMP2A and serves to regulate the stability of LMP2A and LMP2A-kinase complexes. Furthermore, stable expression of LMP2A in Jurkat T cells down-regulated T cell receptor levels and attenuated T cell receptor signaling. Thus, through recruiting tyrosine kinases involved in T cell receptor activation, LMP2A may provide a survival signal for EBV-positive T cell tumors, whereas LMP2A-associated NEDD4 E3 ligases probably titer the strength of this signal.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Epstein-Barr virus (EBV)4 is a {gamma}-herpesvirus that causes infectious mononucleosis and is associated with a number of human cancers, including Burkitt lymphoma and nasopharyngeal carcinoma (reviewed in Refs. 1 and 2). Infection is common, and it is estimated that ~90% of the world's population is latently infected with EBV (3). This latent infection is maintained in the body's memory B cells through the expression of a number of latency-associated viral genes, one of which is latent membrane protein 2A (LMP2A) (4).

LMP2A is a 12-membrane-spanning polypeptide with intracellular amino- and carboxyl termini. It has been reported to aggregate into "cap-like" structures at the plasma membrane (5, 6) and specifically associate with lipid rafts (7, 8); however, LMP2A has also been shown to localize to the Golgi and endocytic vesicles (9, 10). Also, the C-terminal tail of LMP2A has been reported to possess a clustering signal (11).

LMP2A is thought to maintain B cells in the latent state by interfering with signaling through the B cell receptor (BCR) and thus prevent activation of the lytic promoting viral BZLF-1 gene (4, 12). The ability of LMP2A to interfere with BCR signaling and maintain viral latency is due to a number of protein-protein interaction motifs located within the amino-terminal tail (see Fig. 1). These include a YEEA site that, when phosphorylated on the tyrosine residue (Tyr112), can bind the Src homology 2 domain of the Src family tyrosine kinase Lyn (12-14). In addition, LMP2A possesses an immunoreceptor tyrosine-based activation motif (ITAM) motif with the consensus sequence YXX(I/V)X6-8-YXX(I/V), which is found in a number of immunoreceptors including the BCR, the T cell receptor (TCR), and the Fc{epsilon} receptor that binds IgE (15). This motif in LMP2A, when phosphorylated on tyrosines 74 and 85, provides a binding site for the dual Src homology 2 domains of the tyrosine kinase Syk (16, 17). LMP2A also possesses two PPPPY (PY) motifs that can bind to the WW domains of the NEDD4 family of E3 ubiquitin ligases, including AIP4, NEDD4-2, and WWP2 (18-20). Binding to NEDD4 proteins is abrogated by mutation of both tyrosines in the PY motifs (Tyr60 and Tyr101). NEDD4 family proteins contain HECT (homologous to E6-associated protein carboxyl terminus) domains that catalyze the ubiquitylation of proteins such as those associated with the WW domains and target them for degradation via either the 26 S proteasome or a lysosomal pathway (21). LMP2A and the LMP2A-associated kinases are substrates for the NEDD4 family of proteins, suggesting that LMP2A may not only sequester tyrosine kinases away from the BCR but may also direct them to ubiquitin-mediated pathways such as degradation.

Somewhat paradoxically, LMP2A has also been shown to mimic BCR signaling. When expressed as a transgene specifically in the B-lineage in mice, LMP2A can both drive B cell development and promote the survival of mature B cells in the absence of surface Ig expression (22-24). Furthermore, this signal appears to be attenuated by the NEDD4 family protein, Itch, since crossing mice homozygous for a deficiency in Itch into the LMP2A transgenic background enhanced LMP2A-mediated signaling (25). Therefore, LMP2A may provide a survival factor for EBV-positive B cell tumors that have lost expression of surface Ig as well as preventing virus reactivation.

EBV can also infect T cells and is found associated with a wide range of peripheral T cell and NK-/T-cell lymphomas, particularly localized to the upper respiratory tract (26, 27). These lymphomas are particularly prevalent in Southeast Asia, overlapping with the high incidence region for nasopharyngeal carcinoma (28). EBV-positive T cell malignancies are also associated with Japanese patients with chronic active EBV infection and EBV-associated hemophagocytic syndrome (29-32). In these potentially fatal disorders, EBV-infected T cells produce large numbers of proinflammatory cytokines such as interferon-{gamma} and tumor necrosis factor-{alpha} that cause fever, hepatomegaly, and splenomegaly, with patients often succumbing to hepatic or cardiac problems. Whereas LMP1 has been suggested to regulate cytokine production in these EBV-infected T cells (33), they also express LMP2A (34), but the function of LMP2A in these and other T cell malignancies (35) has not been established. In this regard, the similarities between BCR and TCR signaling raise the possibility that LMP2A may be able to manipulate TCR signaling as it does BCR signaling. We have therefore, examined the potential functions of LMP2A in T cells. Here we show that in the Jurkat T antigen (TAg) human T cell line, LMP2A is tyrosine-phosphorylated and associates with the tyrosine kinases Lck and ZAP-70 through the phosphorylated YEEA and ITAM motifs, respectively. Also, the two PY motifs in LMP2A bind the NEDD4 family E3 ubiquitin ligase AIP4 in T cells, which can consequently ubiquitylate LMP2A. Mutation of the PY motifs in LMP2A greatly stabilizes the protein and increases the stability of LMP2A-kinase complexes. This may have the consequence of titering signaling through LMP2A. In this model system, stable expression of LMP2A down-regulated TCR levels and moderately inhibited signaling events downstream of the TCR. Our demonstration that LMP2A interacts with key T cell signaling proteins suggests a role for this viral protein in EBV-positive T cell tumors.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Antibodies, Constructs, and Other Reagents—The M2 anti-FLAG monoclonal antibody (mAb) and anti-{alpha}-tubulin mAb, DM 1A, were purchased from Sigma. The anti-LMP2A rat mAb, 14B7, was purchased from ITN GmbH (Neuherberg, Germany). The anti-Lck, anti-Fyn, anti-Syk polyclonal, and anti-ZAP-70 antisera were provided by Dr André Veillette (McGill University, Montreal, Canada). The anti-AIP4 polyclonal antiserum has been previously described (18). The 4G10 anti-phosphotyrosine (Tyr(P)) mAb and anti-Erk polyclonal antiserum were purchased from Upstate%20Biotechnology">Upstate Biotechnology Inc. (Lake Placid, NY). The anti-Myc mAb, 9E10, and anti-HA antiserum were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The anti-ZAP-70 mAb was purchased from BD Transduction Laboratories (Mississauga, Canada). The phosphospecific anti-phospho-Erk (Thr202, Tyr204) and phospho-ZAP-70 (Tyr319) antisera were purchased from Cell Signaling Technologies (Beverly, MA). The phycoerythrin (PE)-conjugated anti-CD{epsilon} (UCHT1), anti-CD69 (H1.2F3), anti-CD28 (CD28.2), and isotype control mAbs were purchased from BD Biosciences (Mississauga, Canada).

The Myc-tagged murine ZAP-70 was provided by Dr. Andrey Shaw (Washington University, St Louis, MO). The HA-ubiquitin construct was a gift from Dr. Ivan Dikic (Goethe University Medical School, Frankfurt, Germany). The mutant LMP2A constructs (see Fig. 1) have either been previously described (18) or were generated by PCR and sequence-verified. The 4x FLAG constructs were generated by cloning singly FLAG-tagged LMP2A constructs into the pCMV 3x FLAG vector (Sigma). The resulting proteins consist of three FLAG epitopes, a spacer of 14 amino acids, an additional FLAG epitope, and a spacer of 6 amino acids, followed by the LMP2A protein. The doubly Myc-tagged AIP4 constructs were generated by PCR of our previously published constructs (18) with the amino terminus of the published AIP4 sequence (19) replacing the amino-terminal Itch portion of the fusion used in our earlier study. These constructs were cloned into the pCDNA3.1A expression vector (Invitrogen). The synthesis of the biotinylated peptides has been previously described (18) with peptide sequences indicated in Fig. 1.

Cell Lines and Tissue Culture—Jurkat, Jurkat TAg, and the Syk/ZAP-70-deficient (P116) T cells were obtained from Dr. André Veillette. The JCAM-1 cells (Lck-deficient) and JCAM-1 cells reconstituted with Lck were a gift from Dr. David Strauss (Virginia Commonwealth University, Richmond, VA). Cells were grown in RPMI 1640 medium (Invitrogen) supplemented with 10% fetal calf serum (Invitrogen). The stable LMP2A-expressing Jurkat cell lines were generated using retrovirus-mediated gene transfer using the pLXPOP vector containing the LMP2A cDNA (18) and the primate-tropic packaging line, PG13 (36). Stably expressing cells were selected in 2 µg/ml puromycin, and LMP2A expression was verified by anti-LMP2A immunoblotting.

Transfection of Jurkat and Jurkat-derivative Cell Lines—Jurkat or derivative cell lines were electroporated with a BTX ECM 830 square wave electroporator (BTX, San Diego, CA) with three 225-V pulses of 8-ms pulse length and waiting for 1 s between pulses. The total amount of DNA electroporated in each experiment, indicated in the figures and figure legends, was kept constant through the addition of empty vector. After electroporation, cells were resuspended in fresh RPMI 1640 medium and incubated for 24 h at 37 °C.

Cell Lysis and Precipitations—Cells were collected by centrifugation at ~500 x g at 24 h post-electroporation and lysed in 1% Nonidet P-40 lysis buffer (1% Nonidet P-40, 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 mM sodium vanadate, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, 10 µg/ml aprotinin) for 15 min on a rocker in the cold. Detergent-insoluble material was removed by centrifugation of the lysate at ~18,000 x g for 10 min. Cleared lysates were incubated with 2-4 µg of the indicated antibodies and either protein A- or G-Sepharose or anti-mouse Ig agarose for 1 h on a rocker at 4 °C. Immunoprecipitates were then washed three times with Nonidet P-40 lysis buffer, and bound proteins were eluted by boiling in SDS-PAGE sample buffer. For precipitations with the biotinylated peptides, 10 µl of peptide-saturated streptavidin-agarose beads, corresponding to ~1 nmol of peptide, was used. Dephosphorylation of the tyrosine-phosphorylated peptides was achieved by incubating the peptides on streptavidin-agarose with 1 unit of calf intestinal phosphatase (Roche Applied Science) for 1 h at 37 °C prior to performing precipitation experiments.

Western Blotting—Samples were run out on SDS-polyacrylamide gels, transferred to nitrocellulose, and blocked in 5% skim milk powder in Tris-buffered saline containing 0.05% Tween 20 (TBST) or 5% bovine serum albumin in TBST. Blots were incubated with primary Ab in TBST with 5% bovine serum albumin either overnight at 4 °C or 1 h at room temperature. Blots were then rinsed several times in TBST followed by incubation with a secondary Ab, either goat anti-mouse, goat anti-rabbit, or protein A-horseradish peroxidase-coupled reagent (Bio-Rad) for 1 h at room temperature. Blots were rinsed several times in TBST and, finally, rinsed once in TBS before being exposed to enhanced chemiluminescence reagent (Pierce). Blots were stripped with TBST, pH 2, for 30 min before being reprobed as above.

Cycloheximide and Ubiquitylation Experiments—For cycloheximide experiments, Jurkat TAg cells were transfected with the indicated plasmids and incubated for 24 h at 37 °C. Cells were then either left untreated or treated for the indicated times with 10 µg/ml cycloheximide (Sigma) prior to lysing the cells as described above. For ubiquitylation experiments, transfected cells were grown for 24 h and then treated for 1 h with 50 µM of the proteasome inhibitor MG132 (BACHEM, King of Prussia, PA). Cells were then lysed as described above with the exception that 50 µM MG132 and 20 mM N-ethylmaleimide (Sigma) was added to the lysis buffer.



View larger version (6K):
[in this window]
[in a new window]
  		FIGURE 1.
Sequence of the amino-terminal tail of LMP2A. The Src family kinase (Y112), Syk (ITAM), and NEDD4 family (PPPPY-1 and -2) binding sites are indicated in boldface type. The sequences corresponding to biotinylated peptides used for precipitation experiments are underlined, with phosphorylated tyrosine residues, where applicable, indicated with an asterisk. The PPPPY peptides were synthesized as both phosphorylated (PPPPpY) and nonphosphorylated (PPPPY) peptides. The Y112 and ITAM peptides were synthesized as singly and doubly phosphorylated peptides, respectively (pY112 and pITAM) and were treated with alkaline phosphatase to dephosphorylate the peptides (Y112 and ITAM).

 
Stimulation of Jurkat T Cells—Jurkat T cells were resuspended to 1 x 107/ml in RPMI 1640 medium. 1 ml of the cell suspension was incubated with the anti-TCR CD3{epsilon} chain mAb, OKT3, anti-CD28 mAb (a gift from Dr. Philippe Poussier, University of Toronto, Toronto, Canada), or both at 10 µg/ml for 30 min on ice with occasional mixing. The cells were then pelleted and rinsed with serum-free RPMI. Cells were then resuspended in 100 µl of fresh RPMI 1640 medium (no serum) containing 20 µg/ml goat anti-mouse IgG (Bio-Can, Mississauga, Canada) for the indicated times at 37 °C. The reaction was stopped by adding 500 µl of cold phosphate-buffered saline containing 1 mM sodium vanadate. Cells were then spun down and lysed in 1% Nonidet P-40 lysis buffer as described above, and the protein concentration of the cleared lysate was determined by a BCA assay (Pierce).

Fluorescence-activated Cell Sorting—1 x 106 cells were pelleted and washed in FACS buffer (phosphate-buffered saline containing 1% serum and 0.02% NaN3). Cells were resuspended in 50 µl of FACS buffer to which 20 µl of PE-conjugated Ab was added. Cells were incubated for 30 min on ice with occasional mixing and washed a final time with FACS buffer before being resuspended in 1 ml of FACS buffer and analyzed on a BD Biosciences FACSCalibur cell sorter. For stimulation of cells prior to sorting, 5 x 105 cells were incubated for 24 h with 2 µg of the anti-CD3 mAb (UCHT1) or 50 ng/ml phorbol 12-myristate 13-acetate in 24-well plates.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Expression of LMP2A and LMP2A Mutant Constructs in Jurkat TAg Cells—To explore if LMP2A is tyrosine-phosphorylated in T cells, associates with T cell tyrosine kinases, and affects TCR signaling, we expressed wild type (WT) LMP2A containing a quadruple FLAG tag at the amino terminus (4x FLAG-LMP2A) in Jurkat TAg cells (Fig. 2). In addition, we constructed mutants in the 4x FLAG background that lack the putative binding sites for Src family tyrosine kinases (Y112F; SFK-), the tandem Src homology 2 domains of the Syk/ZAP-70 tyrosine kinases (Y74/85F; ITAM-), or the WW domains of NEDD4 family E3 ubiquitin ligases (Y60/101A; PY-) (see Fig. 1). To first assess the relative expression level of the different 4x FLAG-tagged LMP2A proteins, expression vectors encoding WT or mutant LMP2A were electroporated into Jurkat TAg cells, and expression was assessed 24 h post-transfection (Fig. 2A, upper panel). The expression level of the PY- mutant with substitutions in both PPPPY motifs was consistently severalfold higher than either WT LMP2A or any of the other mutant proteins (Fig. 2A, upper panel). Titering the amount of transfected cDNA for the WT and PY- mutant showed that the mutant was expressed at 5-10 times the level of the WT protein (Fig. 2B, upper panel). Furthermore, incorporating substitutions in either the SFK (Y112F) binding site or the ITAM (Y74/85F) motif into the PY- mutant background (4x FLAG-PY-/SFK- LMP2A and 4x FLAG-PY-/ITAM- LMP2A, respectively) significantly increased the expression levels of both the SFK- and ITAM- mutants (Fig. 2C, upper panel). To determine whether the increased level of the PY- mutant was due to stabilization of the LMP2A protein, we treated Jurkat TAg cells with cycloheximide and compared the stability of the WT and PY- mutant proteins. The WT protein showed a significant decrease in expression over time in the cycloheximide-treated samples that was attenuated with the PY- mutant (Fig. 2D). This was especially evident at the 12-h time point. Taken together, these data suggest a role for the PY motifs in controlling the stability of LMP2A in Jurkat TAg cells.

LMP2A Associates with the NEDD4 Family Protein, AIP4, and Is Ubiquitylated in Jurkat TAg Cells—Since mutation of the PY motifs within LMP2A has previously been shown to abolish interaction with the NEDD4 family of E3 ubiquitin ligases in B cells (18, 20), the increased abundance and stability of this mutant protein in Jurkat TAg T cells may reflect an inability to bind NEDD4 family proteins and consequently a defect in ubiquitylation and degradation. We therefore tested whether WT LMP2A associates with the NEDD4 family member AIP4 in Jurkat TAg cells. Fig. 3A shows that endogenous AIP4 co-precipitates with WT LMP2A (4x FLAG-LMP2A) and with the putative Src family kinase (4x FLAG-SFK- LMP2A) and ITAM (4x FLAG-ITAM- LMP2A) mutants, but not with the PY- mutant (4x FLAG-PY- LMP2A) in Jurkat TAg cells. Thus, LMP2A associates with NEDD4 family proteins through its PY motifs in Jurkat T cells, and the inability to bind this family of proteins correlates with an increase in LMP2A stability. We therefore next tested whether LMP2A was ubiquitylated in Jurkat TAg cells. Co-transfection of Jurkat TAg cells with FLAG-tagged LMP2A and an HA-tagged ubiquitin construct showed that the HA-tagged ubiquitin was incorporated into LMP2A, with species probably corresponding to mono-, di-, and tri-ubiquitylated LMP2A predominating (Fig. 3B, upper panel; indicated with arrows). Co-transfection of a Myc-tagged AIP4 construct enhanced LMP2A ubiquitylation, whereas co-transfecting a Myc-tagged mutant AIP4 protein that had been rendered enzymatically inactive by mutation of the catalytic cysteine (Myc-C830A AIP4) did not augment (and in most experiments slightly inhibited) the ubiquitylation of LMP2A in Jurkat TAg cells. Since we could readily identify ubiquitylation of LMP2A in Jurkat TAg cells, we tested whether the PY- LMP2A mutant was detectably ubiquitylated. cDNAs encoding the 4x FLAG-LMP2A or 4x FLAG-PY- LMP2A were co-transfected with the HA-tagged ubiquitin into Jurkat TAg cells. To equalize for protein expression, one-fifth the amount of the cDNA was transfected for the PY- mutant. The results show that in contrast to the WT protein, the PY- LMP2A mutant that lacks binding sites for the WW domains of AIP4 was not appreciably ubiquitylated in these cells (Fig. 3C, upper panel). Therefore, LMP2A is ubiquitylated by NEDD4 family E3 protein-ubiquitin ligases in Jurkat TAg cells, and the lack of ubiquitylation of the PY- mutant probably explains the increased stability of this protein.



View larger version (12K):
[in this window]
[in a new window]
  		FIGURE 2.
The PY- mutant is stabilized in Jurkat TAg cells. A, Jurkat TAg cells were electroporated with 50 µg of the indicated plasmids and incubated for 24 h at 37 °C. Cell lysates were prepared and expression of the 4x FLAG-tagged constructs visualized by Western blotting with the M2 anti-FLAG mAb (upper panel). The blot was subsequently stripped and reprobed with an anti-{alpha}-tubulin antibody to show equal loading (lower panel). B, Jurkat TAg cells were transfected with the plasmids at the indicated amounts and incubated for 24 h at 37 °C. Cell lysates were immunoblotted as in A. C, Jurkat TAg cells were electroporated with 50 µg of the indicated plasmids and incubated for 24 h at 37 °C. Cells lysates were immunoblotted as in A. D, Jurkat TAg cells were transfected with 50µg of the indicated plasmids and incubated for 24 h at 37 °C. The cells were then either left untreated (-) or treated with 10 µg/ml cycloheximide (+) for the indicated times prior to lysis and blotting the lysates as in A. Molecular mass standards (in kDa) are indicated on the left of each blot.

 
LMP2A Is Tyrosine-phosphorylated in Jurkat TAg Cells, Which Requires T Cell Src Family Tyrosine Kinases—In B cells, LMP2A is highly tyrosine-phosphorylated (6). To determine whether this was also apparent in T cells, we transfected into the Jurkat TAg cell line either the 4x FLAG-LMP2A or PY- mutant and looked at the tyrosine phosphorylation of LMP2A. Again, less DNA was transfected for the PY- mutant to normalize for the increased stability of this mutant. As seen in Fig. 4A (upper panel), LMP2A is tyrosine-phosphorylated in Jurkat TAg cells. Interestingly, the PY- mutant was substantially hyperphosphorylated relative to the WT protein despite a similar level of protein expression (Fig. 4A, upper and lower panels, respectively). No additional tyrosine-phosphorylated proteins were seen in the immunoprecipitates of either the WT or PY- mutant LMP2A proteins. To determine whether mutation of the putative Src family kinase-binding site and ITAM motif affected the phosphorylation of LMP2A, we examined the phosphorylation of these mutants in the context of the PY- background (due to the increased phosphotyrosine signal of the PY- mutant). When compared with the 4x FLAG-PY- LMP2A protein, the 4x FLAG-PY-/SFK- LMP2A double mutant was severely reduced in phosphorylation, whereas the PY-/ITAM- mutant retained a significant level of phosphorylation (Fig. 4B, upper panel). Since LMP2A is tyrosine-phosphorylated in Jurkat TAg cells, we next explored which tyrosine kinase(s) in T cells might be responsible for phosphorylating LMP2A. In B cells, LMP2A associates with both the Src family tyrosine kinase Lyn and the Syk tyrosine kinase (12-14, 16, 17). Therefore, we tested whether the analogous T cell kinases, the Src family tyrosine kinases Lck and Fyn on the one hand and Syk and the related kinase ZAP-70 on the other, were required for phosphorylation of LMP2A in T cells. To do this, we made use of variants of the Jurkat cell line, including P116 cells, which are deficient in both Syk and ZAP-70 expression (37) (Fig. 4C, lower panel) and JCAM-1 cells, which lack Lck and are reduced in Fyn expression (38) (Fig. 4C, lower panel). Whereas the level of tyrosine phosphorylation of the 4x FLAG PY- LMP2A in the P116 cells was indistinguishable from the parental cell line, tyrosine phosphorylation of the 4x FLAG-PY- LMP2A was virtually absent in JCAM-1 cells (Fig. 4C, upper panel). The importance of Lck for the phosphorylation of LMP2A was further investigated by looking at LMP2A phosphorylation in JCAM-1 cells that had been reconstituted with Lck. Fig. 4D (upper panel) shows that reconstitution of JCAM-1 cells with Lck was able to restore LMP2A tyrosine phosphorylation to levels seen in the parental Jurkat line. Thus, Src family kinases are required for phosphorylation of LMP2A in Jurkat T cells; we therefore examined whether Lck and other tyrosine kinases in T cells could associate with LMP2A.

LMP2A Associates with Several Tyrosine Kinases in Jurkat TAg Cells—Since Lck is important for LMP2A tyrosine phosphorylation in Jurkat cells, we first examined whether Lck associates with LMP2A in these cells. Fig. 5A (upper panel) shows that 4x FLAG-LMP2A co-precipitates with Lck in anti-Lck immunoprecipitates. Furthermore, the PY- LMP2A mutant was greatly enhanced in its ability to co-precipitate with Lck in immunoprecipitates of Jurkat TAg cell lysates (Fig. 5A). To assess which motifs in LMP2A are required for its binding to Lck, we transfected the PY-/SFK-, and PY-/ITAM- mutants into Jurkat TAg cells and looked at the ability of these mutants to precipitate Lck from Jurkat TAg cells as compared with the PY- mutant. As expected, the PY-/SFK- mutant was unable to form a stable complex with Lck, whereas the PY-/ITAM- mutant co-precipitated with Lck to levels comparable with the PY- mutant (Fig. 5B, upper panel). Similar results were also obtained for the additional T cell Src family tyrosine kinase, Fyn (Fig. 5B, lower panels).



View larger version (15K):
[in this window]
[in a new window]
  		FIGURE 3.
LMP2A associates with the NEDD4 family protein, AIP4, and is ubiquitylated in Jurkat TAg cells. A, Jurkat TAg cells were transfected with 25 µg of the indicated plasmids and incubated for 24 h at 37 °C. Cell lysates were immunoprecipitated with the M2 anti-FLAG mAb, and precipitated proteins were analyzed by immunoblotting with an anti-AIP4 polyclonal antiserum (upper panel). The blot was then stripped and reprobed with the M2 anti-FLAG mAb (lower panel). B, Jurkat TAg cells were transfected with the indicated plasmids and incubated for 24 h at 37 °C. Cells were treated with 50 µM MG132 1 h prior to lysis and lysed in lysis buffer containing 50 µM MG132 and 20 mM N-ethylmaleimide. Lysates were immunoprecipitated with the 14B7 anti-LMP2A rat mAb, and precipitated proteins were analyzed for ubiquitylated proteins by immunoblotting with an anti-HA polyclonal antiserum (upper panel). The likely mono-, di-, and triubiquitylated FLAG-tagged LMP2A species are indicated with arrows. The anti-HA reactive bands indicated with asterisks are probably ubiquitylated AIP4 co-precipitating with LMP2A. The blot was then stripped and reprobed with the anti-FLAG mAb (middle panel) and anti-Myc mAb (lower panel). The FLAG-tagged, nonubiquitylated LMP2A and Myc-tagged AIP4 proteins are indicated with arrows. C, Jurkat TAg cells were transfected with the incubated constructs and treated as in B. Blots were probed with the anti-HA polyclonal antiserum (upper panel) and then stripped and reprobed with the M2 anti-FLAG mAb (lower panel). The likely mono-, di-, and triubiquitylated, FLAG-tagged LMP2A species (upper panel) and nonubiquitylated, FLAG-tagged LMP2A (lower panel) are indicated with arrows. In relevant blots, the Ig heavy chain of the immunoprecipitating Ab is indicated (IgH). Molecular mass standards (in kDa) are indicated on the left of each blot.

 
We also inspected the association of ZAP-70 with LMP2A in T cells. To do this, we used a Myc-tagged ZAP-70 construct due to high levels of nonspecific binding seen with the antibody used to precipitate the endogenous ZAP-70 protein. Co-expressing a Myc-tagged ZAP-70 construct with the 4x FLAG-tagged LMP2A or PY- mutant showed that ZAP-70 and LMP2A co-precipitate in Jurkat TAg cells, with slightly increased ZAP-70 binding seen with the PY- mutant (Fig. 5C, upper panel). Experiments performed to examine the requirements for ZAP-70 binding to LMP2A showed that mutation of either the Src kinase-binding site or the ITAM motif inhibited association with the Myc-tagged ZAP-70 (Fig. 5D, upper panel). To further characterize the association of ZAP-70 with LMP2A, we found that a biotinylated peptide of the doubly phosphorylated ITAM peptide (pITAM), but not the corresponding dephosphorylated peptide (ITAM), selectively precipitated ZAP-70 (Fig. 5E, upper panel) and Syk (Fig. 5E, lower panel) from Jurkat lysate. Thus, LMP2A recruits T cell tyrosine kinases in a manner similar to that seen in B cells.

LMP2A Interferes with TCR Signaling in Jurkat T Cells—Since recruitment of the Lyn and Syk tyrosine kinases to LMP2A in B cells is important for the LMP2A-mediated inhibition of BCR signaling, we investigated whether expression of LMP2A in T cells similarly inhibited TCR signaling. To this end, we generated Jurkat T cell lines that stably expressed LMP2A (clones 3 and 5). Fig. 6A shows that LMP2A is expressed and tyrosine-phosphorylated in these cell lines. Examination of TCR (CD3) cell surface expression by FACS analysis showed that there was a decrease in TCR surface expression in the LMP2A-expressing cells as compared with the parental line (Fig. 6B). Stimulation of the LMP2A-expressing cell lines and the parental cell line with antibodies directed against the CD3 portion of the TCR showed that TCR-mediated induction of tyrosine-phosphorylated proteins was slightly attenuated in the LMP2A-expressing cells relative to the parental cell line (Fig. 6C). Using antibodies that recognize the phosphorylated, active forms of ZAP-70 and the Erk1 and -2 serine/threonine kinases (Fig. 6D) showed that TCR-mediated activation of these kinases was reduced in LMP2A-expressing cells relative to the parental cell line. The effect of LMP2A on TCR signaling was further examined by investigating the expression of the early T cell activation marker, CD69. CD69 expression was reduced in both the unstimulated and TCR-stimulated LMP2A-expressing cell lines relative to the parental control (Fig. 6E). Thus, expression of LMP2A in Jurkat T cells attenuates TCR signaling. We also observed that the basal levels of cellular tyrosine phosphorylation and ZAP-70 and Erk1 and -2 activation were reduced in the LMP2A-expressing cells relative to the parental line (Fig. 6, C and D).



View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 4.
LMP2A is tyrosine-phosphorylated in Jurkat TAg cells, in a fashion that requires T cell Src family kinases. A, Jurkat TAg cells were transfected with the indicated plasmids (50 µg of 4x FLAG-LMP2A, 10 µg of 4x FLAG-PY- LMP2A) and incubated for 24 h at 37 °C. Cell lysates were immunoprecipitated with the M2 anti-FLAG mAb and precipitated proteins were analyzed by immunoblotting with the 4G10 anti-Tyr(P) mAb (PTyr; upper panel). Tyrosine-phosphorylated, FLAG-tagged LMP2A proteins are indicated with an arrow. Blots were then stripped and reprobed with the M2 anti-FLAG mAb (lower panel), and FLAG-tagged LMP2A proteins are indicated with an arrow. Note that the anti-Tyr(P) blot is a light exposure to illustrate the difference in phosphorylation between the WT and PY- mutant. B, Jurkat TAg cells were transfected with 50 µg of the indicated plasmids and analyzed as in A. Blots were first probed with the 4G10 anti-Tyr(P) mAb (upper panel) and subsequently stripped and reprobed with the M2 anti-FLAG mAb (lower panel). Tyrosine-phosphorylated (upper panel) or FLAG-tagged LMP2A (lower panel) proteins are indicated with arrows. C, Jurkat, JCAM-1, or P116 cells were transfected with 20, 40, or 80 µg of the 4x FLAG-PY- LMP2A, respectively, and incubated for 24 h at 37 °C. Cell lysates were immunoprecipitated with the M2 anti-FLAG mAb, and precipitated proteins were analyzed by immunoblotting with the 4G10 anti-Tyr(P) mAb (upper panel). Tyrosine-phosphorylated LMP2A proteins are indicated with an arrow. Blots were then stripped and reprobed with the M2 anti-FLAG mAb (second panel from top), and FLAG-tagged LMP2A proteins are indicated with the arrow. Cell lysate from the indicated cell lines was analyzed to assess the relative level of ZAP-70 (middle panel), Lck (second panel from bottom), or Fyn (lower panel) in the respective lysates. D, Jurkat cells, JCAM-1 cells, or JCAM-1 cells reconstituted with murine Lck were transfected with the indicated plasmids and immunoprecipitated as in A. Blots were first probed with the 4G10 anti-Tyr(P) mAb (upper panel) and subsequently stripped and reprobed with the M2 anti-FLAG mAb (middle panel). Tyrosine-phosphorylated (upper panel) or FLAG-tagged LMP2A (middle panel) proteins are indicated with arrows. Cell lysate is included to show the level of Lck in the respective lysates (lower panel). The Ig heavy chain of the immunoprecipitating Ab is indicated (IgH). Molecular mass standards (in kDa) are indicated to the left of each blot.

 
In order for T cells to become activated, they require additional signals from antigen presenting cells including those generated through CD28 (reviewed in Ref. 39). Since CD28 has been shown to recruit the Fyn tyrosine kinase (40-42), we examined whether CD28 and TCR co-stimulation was affected in LMP2A-expressing Jurkat T cells. Fig. 7A shows that the levels of CD28 were similar in both the LMP2A-expressing cells and the parental cell line. The co-ligation of CD3 with CD28 showed a modest enhancement in the induction of tyrosine-phosphorylated proteins (Fig. 7B) and activation of the Erk kinases (Fig. 7C) over CD3 engagement alone in the parental cell line and the LMP2A-expressing cell lines. However, similar to what was observed for CD3 stimulation alone (Fig. 6), the induction of tyrosine-phosphorylated proteins (Fig. 7B) and Erk activation (Fig. 7C) upon CD3 and CD28 co-ligation was reduced in LMP2A-expressing cells compared with their normal counterparts. Taken together, these data show that stable expression of LMP2A in Jurkat T cells modestly attenuates TCR signaling.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
The association of EBV with malignancies such as Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, gastric cancer, and subtypes of T cell lymphomas has been appreciated for some time. Although the virus carries genes involved in cell cycle control and apoptosis, it is largely unknown how EBV contributes to the pathogenesis of these cancers. Therefore, we have examined the role of the EBV protein LMP2A in T cells in order to understand how LMP2A might contribute to EBV-positive T cell lymphomagenesis.



View larger version (13K):
[in this window]
[in a new window]
  		FIGURE 5.
LMP2A associates with tyrosine kinases in Jurkat TAg cells. A, Jurkat TAg cells were transfected with the indicated plasmids (50 µg of 4x FLAG-LMP2A, 10 µg of 4x FLAG-PY- LMP2A) and incubated for 24 h at 37 °C. Cell lysates were immunoprecipitated with either the anti-Lck polyclonal antiserum or control antiserum, and precipitated proteins were analyzed by immunoblotting with the M2 anti-FLAG mAb (upper panel). Blots were then stripped and reprobed with the anti-Lck polyclonal antiserum (middle panel). Cell lysate is included to show the relative expression of the respective 4x FLAG-tagged LMP2A constructs (lower panel). B, Jurkat TAg cells were transfected with 50µg of the indicated plasmids and incubated for 24 h at 37 °C. Cell lysates were immunoprecipitated with the M2 anti-FLAG mAb, and precipitated proteins were analyzed by immunoblotting with either the anti-Lck polyclonal antiserum or an anti-Fyn polyclonal antiserum. Blots were stripped and reprobed with the M2 anti-FLAG mAb (lower panels). C, Jurkat TAg cells were transfected with the indicated plasmids and incubated for 24 h at 37 °C. Cell lysates were immunoprecipitated with the 9E10 anti-Myc mAb or control mAb, and precipitated proteins were analyzed by immunoblotting with the M2 anti-FLAG mAb (upper panel). The FLAG-tagged LMP2A proteins are indicated with an arrow, and the Ig heavy chain of the immunoprecipitating Ab (IgH) is also indicated. Blots were then stripped and reprobed with the anti-Myc mAb (middle panel). Cell lysate is included to show the relative expression of the respective 4x FLAG-tagged LMP2A constructs (lower panel). D, Jurkat TAg cells were transfected with 25 µg of the indicated plasmids and incubated for 24 h at 37 °C. Cell lysates were immunoprecipitated with the 9E10 anti-Myc mAb or control mAb, and precipitated proteins were analyzed by immunoblotting with the M2 anti-FLAG mAb (upper panel). Blots were stripped and reprobed with the anti-Myc mAb (middle panel). Cell lysate is included to show the relative expression of the respective 4x FLAG-tagged LMP2A constructs (lower panel). E, the indicated peptides were used to precipitate proteins from Jurkat cell lysate, and precipitated proteins were analyzed by immunoblotting with the anti-ZAP-70 polyclonal antiserum (upper panel) or anti-Syk polyclonal antiserum (lower panel). Molecular mass standards (in kDa) are indicated to the left of each blot.

 
Our data show that LMP2A expressed in T cells recruits a number of cytoplasmic proteins normally involved in TCR signaling in a similar fashion to LMP2A in B cells. The use of mutant forms of LMP2A and peptides representing LMP2A interaction motifs showed that the Src family tyrosine kinases Lck and Fyn are specifically recruited to the phosphorylated Tyr112 site of LMP2A (Fig. 5). Phosphorylation of Tyr112 seems critical for LMP2A to recruit T cell tyrosine kinases, since mutation of this residue to phenylalanine abolished phosphorylation of LMP2A on tyrosine (Fig. 4B) and the subsequent recruitment of Lck, Fyn, and ZAP-70 (Fig. 5). Tyr112 is probably the most prominent tyrosine phosphorylation site on LMP2A in T cells, since mutation of the Tyr112 site abolished LMP2A phosphorylation, whereas mutation of the two tyrosines in the ITAM motif had little effect on the overall level of LMP2A tyrosine phosphorylation (Fig. 4B). Despite the prominence of Tyr112 phosphorylation, our data indicate that LMP2A recruits ZAP-70, which, based on the analysis of peptide pull-downs and LMP2A mutants, requires phosphorylation of the ITAM motif (Fig. 5).

The importance of the Src family tyrosine kinases for phosphorylation of LMP2A in Jurkat T cells was further demonstrated by the lack of LMP2A tyrosine phosphorylation in the Lck-deficient JCAM-1 cells, which also have reduced levels of Fyn (Fig. 5C). Since some Fyn is expressed in JCAM-1 cells, it is possible that Lck is a more active kinase for LMP2A in vivo than Fyn. Alternatively, a threshold level of total Src family kinase activity may be necessary for phosphorylation of LMP2A in Jurkat T cells. The fact that tyrosine phosphorylation of LMP2A was not reduced in the ZAP-70/Syk-deficient P116 cells shows that although these kinases are recruited to LMP2A, they play no significant role in the phosphorylation of LMP2A itself.

Our results also show that LMP2A associates with the NEDD4 family E3 ubiquitin ligase AIP4 and that LMP2A is polyubiquitylated in Jurkat T cells. Furthermore, mutation of the two PY motifs abolished binding of the NEDD4 family of proteins (Fig. 3A) and led to a strong stabilization of LMP2A (Fig. 2). Mutation of the two PY motifs has previously been shown to increase the stability of LMP2A in lymphoblastoid cell lines (20). However, in that study, mutation of the two PY motifs showed an approximately 2-fold increase in the level of the PY- mutant as compared with the WT protein, which is significantly lower than the 5-10-fold increase that we observed (Fig. 2B). This difference could be due to a difference in the intrinsic stability of LMP2A in lymphoblastoid cell line B cells and Jurkat TAg cells, or alternatively, it might be due to the nature of the constructs used in each study. Whereas Ikeda et al. (20) used untagged LMP2A, we used a 4x FLAG-tagged LMP2A. Unlike most proteins that are ubiquitylated on lysine residues, LMP2A has been proposed to be ubiquitylated at the amino terminus, since a mutant LMP2A protein lacking all 3 lysine residues was still efficiently ubiquitylated (43). Of the 3 lysine residues in LMP2A, none are in the amino-terminal tail, and only 2 are predicted to be intracellular. The addition of the 4x FLAG epitope to the amino terminus adds an additional 5 lysine residues, which may be more readily ubiquitylated than the amino terminus and thus lead to the decreased stability seen for any of the 4x FLAG-tagged with intact PY motifs (see Fig. 2).



View larger version (32K):
[in this window]
[in a new window]
  		FIGURE 6.
LMP2A titers TCR signaling when stably expressed in Jurkat cells. A, cell lysates of the parental cell line or stable LMP2A-expressing cell lines (clones 3 and 5) were immunoprecipitated with the 14B7 anti-LMP2A mAb, and precipitated proteins were analyzed by immunoblotting with the 4G10 anti-Tyr(P) mAb (PTyr; upper panel). LMP2A expression in the indicated cell lysates was assessed by immunoblotting with the 14B7 anti-LMP2A mAb (lower panel). Tyrosine-phosphorylated LMP2A proteins are indicated by the arrow. The Ig heavy chain of the immunoprecipitating Ab is indicated (IgH). B, Jurkat cells stably expressing LMP2A (clones 3 and 5) or the parental cell line were stained with the PE-conjugated anti-CD3{epsilon} mAb, UCHT-1, as described under "Experimental Procedures," and cell surface expression of CD3 was assessed by FACS. The parental line is indicated in black, clone 3 is shown in green, clone 5 is shown in red, and the PE-conjugated, isotype control Ab is shown in blue. C, the cell lines indicated in A were stimulated with or without the anti-CD3{epsilon} mAb, OKT3, for the indicated times as described under "Experimental Procedures." Cell lysates were prepared and analyzed by anti-Tyr(P) immunoblotting (upper panel), whereas LMP2A expression was examined by blotting lysates with the anti-LMP2A mAb (middle panel), and tubulin expression was examined to indicate equal protein loading (lower panel). The arrow indicates the LMP2A protein, and molecular mass standards (in kDa) are indicated to the left of the anti-Tyr(P) blot. D, lysates prepared in C were analyzed for ZAP-70 and Erk activation using phosphospecific Abs directed against the phosphorylated, activated forms of these kinases (respective upper panels). The respective lower panels were probed with anti-ZAP-70 and anti-Erk Abs. E, the indicated cell lines were either left unstimulated or were stimulated for 24 h with the anti-CD3{epsilon} mAb (UCHT-1) at 2 µg/ml or phorbol 12-myristate 13-acetate (PMA; 50 ng/ml). Cells were then stained with a PE-conjugated anti-CD69 mAb. The parental line is indicated in black, clone 3 is shown in green, clone 5 is shown in red, and the PE-conjugated, isotype control Ab is shown in blue. ippts, immunoprecipitates.

 
NEDD4 family proteins not only regulate the stability of LMP2A but also modulate the tyrosine phosphorylation of LMP2A and the recruitment of T cell kinases. When comparing equal levels of protein, the PY- mutant was substantially hyperphosphorylated and precipitated much more Lck and slightly more ZAP-70 than the WT protein (Fig. 4 and 5, respectively). The simplest interpretation of these results is that the NEDD4 family proteins also target LMP2A-associated kinases and that the failure of the PY- mutant to down-regulate these kinases, particularly Lck, leads to increased Lck and ZAP-70 association and consequently increased phosphorylation of LMP2A.

The properties of the LMP2A PY- mutant revealed by these experiments have important implications for the role of NEDD4 family proteins in LMP2A function. For example, in B cells, LMP2A appears to inhibit BCR signaling to maintain viral latency and at the same time mimic aspects of BCR signaling to drive B cell development and act as a survival signal for mature B cells. As illustrated in Fig. 8, our data suggest that positive tyrosine kinase signaling induced by LMP2A is effectively titered through the recruitment of NEDD4 family E3 ubiquitin ligases to the LMP2A PY motifs. This may ensure that downstream signals generated by LMP2A are not strong enough to cause viral reactivation but at the same time are sufficient to provide a weaker survival signal, akin to the antigen-independent signal generated by surface Ig that is required for the survival of mature B cells (22, 23). This latter function has been suggested to be important in EBV-positive Hodgkin B cell lymphomas that express LMP2A but have lost expression of surface Ig (22). TCR expression (44) and the Lck and Fyn tyrosine kinases (45) are required to maintain peripheral naive T cells, raising the possibility that LMP2A-mediated signals could provide a survival signal for EBV-positive T cell tumors.



View larger version (33K):
[in this window]
[in a new window]
  		FIGURE 7.
LMP2A limits signaling through CD3 and CD28. A, Jurkat cells stably expressing LMP2A (clones 3 and 5) or the parental cell line were stained with a PE-conjugated anti-CD28 mAb, as described under "Experimental Procedures," and cell surface expression of CD28 was assessed by FACS. The parental line is indicatedin black, clone 3 is shown in green, clone 5 is shown in red, and the PE-conjugated, isotype control Ab is shown in blue. B, the cell lines indicated in A were either left unstimulated (-), stimulated with anti-CD3 (CD3) or anti-CD28 (CD28) mAbs alone, or stimulated with both anti-CD3 and CD28 (CD3 + 28) together as described under "Experimental Procedures." Cell lysates were prepared and analyzed by anti-Tyr(P) immunoblotting (PTyr; upper panel), whereas LMP2A expression was examined by blotting lysates with the anti-LMP2A mAb (middle panel), and tubulin expression was examined to indicate equal protein loading (lower panel). The arrow indicates the LMP2A protein. C, lysates prepared in B were analyzed for Erk activation using phosphospecific Abs directed against the phosphorylated, activated form of Erk1 and -2 (upper panel). The lower panel was reprobed with the anti-Erk Ab. Molecular mass standards (in kDa) are indicated to the left of the anti-Tyr(P) blot. MAPK, mitogen-activated protein kinase.

 



View larger version (3K):
[in this window]
[in a new window]
  		FIGURE 8.
LMP2A recruits kinases involved in TCR signaling. In T cells, LMP2A recruits Lck (Fyn) and ZAP-70 (Syk) to its tyrosine-phosphorylated Tyr112 and ITAM motifs, respectively. Recruitment of NEDD4 proteins to the two PPPPY motifs leads to ubiquitylation (Ub) of LMP2A and perhaps LMP2A-associated tyrosine kinases, thereby regulating the stability of LMP2A-kinase complexes. This effectively limits the degree of signaling through LMP2A and may be important for providing a weak, tonic signal for the survival of EBV-positive T cell tumors.

 
Our experiments indicate that when stably expressed in Jurkat T cells, LMP2A does abrogate TCR signaling (see Figs. 6 and 7). However, since TCR levels were decreased in the LMP2A-expressing cells, we are unable to distinguish whether the observed decrease in TCR signaling is due to lower levels of TCR, to the sequestering of tyrosine kinases by LMP2A, or to both of these events. A reduction in BCR surface expression has been observed in LMP2A-expressing BJAB cells (46) but not in LMP2A-expressing RAMOS B cells (47). We also found that surface expression of the TCR was down-regulated in Jurkat TAg cells transiently expressing LMP2A (data not shown). We are currently investigating how LMP2A inhibits the surface expression of the TCR.

The recruitment of T cell tyrosine kinases to LMP2A suggests that LMP2A itself has a signaling function in T cells. However, we were unable to see LMP2A-mediated activation of downstream signaling events in Jurkat T cells transiently expressing LMP2A (Fig. 4 and data not shown) or stably expressing LMP2A (Fig. 6). In fact, tyrosine phosphorylation of cellular proteins and activation of ZAP-70 and Erk were reduced in the LMP2A-expressing stable cell lines compared with the parental cell line. It remains possible that LMP2A-induced signals in Jurkat T cells are weak and thus hard to observe or that LMP2A has more pronounced effects in other T cell types. Regardless, our data clearly show that LMP2A recruits key signaling proteins in T cells.

The in vivo role that LMP2A and, for that matter, EBV plays in T cells is still unclear. It is unlikely that T cells represent an additional reservoir for latent infection, and most probably infection of T cells represents a rare, accidental infection that results in an abnormal relationship between virus and host T cell. It will therefore be important in the future to look at the function of LMP2A in T cells in the context of EBV-positive T cell lymphomas and their precursors.


   FOOTNOTES
 
* This work was supported by grants from the Canadian Institutes for Health Research (to T. P.) and the Swedish Cancer Society (to I. E.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 Recipient of a postdoctoral fellowship from the National Cancer Institute of Canada (supported by Funds from the Terry Fox Run) and a Fellow of the Leukemia and Lymphoma Society. Present address: Dept. of Biology, University of Victoria, Petch Bldg. 053, 3800 Finnerty Rd., Victoria, British Columbia V8P 5C2, Canada. Back

2 Recipient of Swedish Research Council Grant K2002-16X-14227-01A and Swedish Children's Cancer Foundation Grant PROJ01/18. Back

3 To whom correspondence should be addressed: Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Ave., Toronto, Ontario M5G 1X5, Canada. Tel.: 416-586-4524; Fax: 416-586-8869; E-mail: pawson{at}mshri.on.ca.

4 The abbreviations used are: EBV, Epstein-Barr virus; LMP2A, latent membrane protein 2A; BCR, B cell antigen receptor; ITAM, immunoreceptor tyrosine-based activation motif; TCR, T cell receptor; PY, PPPPY; TAg, T antigen; mAb, monoclonal antibody; Tyr(P), phosphotyrosine; Ab, antibody; WT, wild type; SFK, Src family kinase; E3, ubiquitin-protein isopeptide ligase; PE, phycoerythrin; FACS, fluorescence-activated cell sorting. Back


   ACKNOWLEDGMENTS
 
We thank Drs. André Veillette, Andrey Shaw, David Straus, Ivan Dikic, Philippe Poussier, and Shosuke Imai for invaluable reagents.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Thorley-Lawson, D. A. (2001) Nat. Rev. Immunol. 1, 75-82[CrossRef][Medline] [Order article via Infotrieve]
  2. Rickinson, A. (2002) Virus Res. 82, 109-113[Medline] [Order article via Infotrieve]
  3. Henle, G., Henle, W., Clifford, P., Diehl, V., Kafuko, G. W., Kirya, B. G., Klein, G., Morrow, R. H., Munube, G. M., Pike, P., Tukei, P. M., and Ziegler, J. L. (1969) J. Natl. Cancer Inst. 43, 1147-1157[Medline] [Order article via Infotrieve]
  4. Miller, C. L., Lee, J. H., Kieff, E., and Longnecker, R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 772-776[Abstract/Free Full Text]
  5. Longnecker, R., and Kieff, E. (1990) J. Virol. 64, 2319-2326[Abstract/Free Full Text]
  6. Longnecker, R., Druker, B., Roberts, T. M., and Kieff, E. (1991) J. Virol. 65, 3681-3692[Abstract/Free Full Text]
  7. Dykstra, M. L., Longnecker, R., and Pierce, S. K. (2001) Immunity 14, 57-67[CrossRef][Medline] [Order article via Infotrieve]
  8. Higuchi, M., Izumi, K. M., and Kieff, E. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 4675-4680[Abstract/Free Full Text]
  9. Lynch, D. T., Zimmerman, J. S., and Rowe, D. T. (2002) J. Gen. Virol. 83, 1025-1035[Abstract/Free Full Text]
  10. Dawson, C. W., George, J. H., Blake, S. M., Longnecker, R., and Young, L. S. (2001) Virology 289, 192-207[CrossRef][Medline] [Order article via Infotrieve]
  11. Matskova, L., Ernberg, I., Pawson, T., and Winberg, G. (2001) J. Virol. 75, 10941-10949[Abstract/Free Full Text]
  12. Miller, C. L., Lee, J. H., Kieff, E., Burkhardt, A. L., Bolen, J. B., and Longnecker, R. (1994) Infect. Agents Dis. 3, 128-136[Medline] [Order article via Infotrieve]
  13. Burkhardt, A. L., Bolen, J. B., Kieff, E., and Longnecker, R. (1992) J. Virol. 66, 5161-5167[Abstract/Free Full Text]
  14. Fruehling, S., Swart, R., Dolwick, K. M., Kremmer, E., and Longnecker, R. (1998) J. Virol. 72, 7796-7806[Abstract/Free Full Text]
  15. Reth, M. (1989) Nature 338, 383-384[Medline] [Order article via Infotrieve]
  16. Fruehling, S., and Longnecker, R. (1997) Virology 235, 241-251[CrossRef][Medline] [Order article via Infotrieve]
  17. Miller, C. L., Burkhardt, A. L., Lee, J. H., Stealey, B., Longnecker, R., Bolen, J. B., and Kieff, E. (1995) Immunity 2, 155-166[CrossRef][Medline] [Order article via Infotrieve]
  18. Winberg, G., Matskova, L., Chen, F., Plant, P., Rotin, D., Gish, G., Ingham, R., Ernberg, I., and Pawson, T. (2000) Mol. Cell. Biol. 20, 8526-8535[Abstract/Free Full Text]
  19. Ikeda, M., Ikeda, A., Longan, L. C., and Longnecker, R. (2000) Virology 268, 178-191[CrossRef][Medline] [Order article via Infotrieve]
  20. Ikeda, M., Ikeda, A., and Longnecker, R. (2001) J. Virol. 75, 5711-5718[Abstract/Free Full Text]
  21. Ingham, R. J., Gish, G., and Pawson, T. (2004) Oncogene 23, 1972-1984[CrossRef][Medline] [Order article via Infotrieve]
  22. Caldwell, R. G., Wilson, J. B., Anderson, S. J., and Longnecker, R. (1998) Immunity 9, 405-411[CrossRef][Medline] [Order article via Infotrieve]
  23. Caldwell, R. G., Brown, R. C., and Longnecker, R. (2000) J. Virol. 74, 1101-1113[Abstract/Free Full Text]
  24. Casola, S., Otipoby, K. L., Alimzhanov, M., Humme, S., Uyttersprot, N., Kutok, J. L., Carroll, M. C., and Rajewsky, K. (2004) Nat. Immunol. 5, 317-327[CrossRef][Medline] [Order article via Infotrieve]
  25. Ikeda, A., Caldwell, R. G., Longnecker, R., and Ikeda, M. (2003) J. Virol. 77, 5529-5534[Abstract/Free Full Text]
  26. Hamilton-Dutoit, S. J., and Pallesen, G. (1992) Am. J. Pathol. 140, 1315-1325[Abstract]
  27. Van Gorp, J., De Bruin, P. C., Sie-Go, D. M., Van Heerde, P., Ossenkoppele, G. J., Rademakers, L. H., Meijer, C. J., and Van Den Tweel, J. G. (1995) Histopathology 27, 139-148[Medline] [Order article via Infotrieve]
  28. Peh, S. C., Sandvej, K., and Pallesen, G. (1995) Int. J. Cancer 61, 327-332[Medline] [Order article via Infotrieve]
  29. Kanegane, H., Nomura, K., Miyawaki, T., Tosato, G., Ohga, S., Nomura, A., Takada, H., and Hara, T. (2002) Crit. Rev. Oncol. Hematol. 44, 239-249[Medline] [Order article via Infotrieve]
  30. Wakiguchi, H. (2002) Crit. Rev. Oncol. Hematol. 44, 193-202[Medline] [Order article via Infotrieve]
  31. Kawa, K., Okamura, T., Yasui, M., Sato, E., and Inoue, M. (2002) Crit. Rev. Oncol. Hematol. 44, 251-257[Medline] [Order article via Infotrieve]
  32. Imashuku, S. (2002) Crit. Rev. Oncol. Hematol. 44, 259-272[Medline] [Order article via Infotrieve]
  33. Lay, J. D., Chuang, S. E., Rowe, M., and Su, I. J. (2003) J. Biomed. Sci. 10, 146-155[Medline] [Order article via Infotrieve]
  34. Imai, S., Sugiura, M., Oikawa, O., Koizumi, S., Hirao, M., Kimura, H., Hayashibara, H., Terai, N., Tsutsumi, H., Oda, T., Chiba, S., and Osato, T. (1996) Blood 87, 1446-1457[Abstract/Free Full Text]
  35. van Gorp, J., Brink, A., Oudejans, J. J., van den Brule, A. J., van den Tweel, J. G., Jiwa, N. M., de Bruin, P. C., and Meijer, C. J. (1996) J. Clin. Pathol. 49, 72-76[Abstract/Free Full Text]
  36. Miller, A. D., Garcia, J. V., von Suhr, N., Lynch, C. M., Wilson, C., and Eiden, M. V. (1991) J. Virol. 65, 2220-2224[Abstract/Free Full Text]
  37. Williams, B. L., Schreiber, K. L., Zhang, W., Wange, R. L., Samelson, L. E., Leibson, P. J., and Abraham, R. T. (1998) Mol. Cell. Biol. 18, 1388-1399[Abstract/Free Full Text]
  38. Straus, D. B., and Weiss, A. (1992) Cell 70, 585-593[CrossRef][Medline] [Order article via Infotrieve]
  39. Greenwald, R. J., Freeman, G. J., and Sharpe, A. H. (2005) Annu. Rev. Immunol. 23, 515-548[CrossRef][Medline] [Order article via Infotrieve]
  40. Hutchcroft, J. E., and Bierer, B. E. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3260-3264[Abstract/Free Full Text]
  41. August, A., and Dupont, B. (1995) Tissue Antigens 46, 155-162[Medline] [Order article via Infotrieve]
  42. Raab, M., Cai, Y. C., Bunnell, S. C., Heyeck, S. D., Berg, L. J., and Rudd, C. E. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8891-8895[Abstract/Free Full Text]
  43. Ikeda, M., Ikeda, A., and Longnecker, R. (2002) Virology 300, 153-159[CrossRef][Medline] [Order article via Infotrieve]
  44. Labrecque, N., Whitfield, L. S., Obst, R., Waltzinger, C., Benoist, C., and Mathis, D. (2001) Immunity 15, 71-82[CrossRef][Medline] [Order article via Infotrieve]
  45. Seddon, B., and Zamoyska, R. (2002) J. Immunol. 169, 2997-3005[Abstract/Free Full Text]
  46. Miller, C. L., Longnecker, R., and Kieff, E. (1993) J. Virol. 67, 3087-3094[Abstract/Free Full Text]
  47. Fukuda, M., and Longnecker, R. (2005) J. Virol. 79, 8655-8660[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mol. Biol. CellHome page
D. Bhandari, S. L. Robia, and A. Marchese
The E3 Ubiquitin Ligase Atrophin Interacting Protein 4 Binds Directly To The Chemokine Receptor CXCR4 Via a Novel WW Domain-mediated Interaction
Mol. Biol. Cell, March 1, 2009; 20(5): 1324 - 1339.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
K. R. Jerome
Viral Modulation of T-Cell Receptor Signaling
J. Virol., May 1, 2008; 82(9): 4194 - 4204.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. G. Clarkson, S. J. Simmonds, M. J. Puklavec, and M. H. Brown
Direct and Indirect Interactions of the Cytoplasmic Region of CD244 (2B4) in Mice and Humans with FYN Kinase
J. Biol. Chem., August 31, 2007; 282(35): 25385 - 25394.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/40/34133    most recent
M507831200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ingham, R. J.
Right arrow Articles by Pawson, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ingham, R. J.
Right arrow Articles by Pawson, T.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement